New Castle, DE - August 2025 - Founded by Zach Taft, IgniteData has closed its Series A funding round led by FCA Venture Partners, with participation from SpringTide, Oncology Ventures, and other strategic backers. The capital will enable the company to scale its clinical site network and expand its flagship product, Archer, which connects electronic health records (EHRs) directly to electronic data capture (EDC) systems - automating one of the most labor-intensive parts of clinical research.

Removing the Manual Burden From Clinical Trials

Clinical trials have historically depended on manual data transcription to transfer patient information from hospital systems into sponsor databases. This process is slow, error-prone, and expensive - often adding weeks of delay and hundreds of hours of redundant clinical staff work. Archer eliminates that bottleneck with real-time, automated data transfer, ensuring that trial sponsors receive structured, validated data directly from the site’s EHR system.

The platform is already running at prominent research centers in North America, Europe, and Asia, handling over 30 million API calls per month and used by 1,500+ clinical professionals.

And this is where the real founder insight reveals itself: IgniteData didn’t try to compete with the massive EDC and EHR vendors or “improve” their workflows. Instead, they built the invisible connective tissue between them. Rather than becoming one more system that clinical teams need to learn, they removed an entire step from the workflow. That’s the kind of product thinking that creates inevitability - because when you eliminate a painful process altogether, you’re no longer competing on features. You’re competing against wasted time. And wasted time never wins.

Fueling the Next Phase of Growth

With the Series A secured, IgniteData plans to:

• Expand its site network to include community hospitals and decentralized research settings
  
• Extend Archer’s coverage into new therapeutic areas such as rare diseases and immune disorders
  
• Deepen integrations with leading EHR and EDC vendors to simplify onboarding and improve interoperability
  

Strong Investor Confidence

FCA Venture Partners brings not only financial capital but deep relationships across integrated delivery networks and research-active health systems. SpringTide and Oncology Ventures’ continued participation underscores the strong traction IgniteData has already demonstrated in real-world trials.

Why This Matters for the Clinical Research Industry

Clinical studies are getting more complex and data-rich, but the underlying processes haven’t evolved. Manual data transcription not only slows down research, it introduces avoidable errors that can threaten validity. With Archer, research teams are able to shift their attention from clerical tasks to actual patient care and trial design - resulting in faster enrollment, cleaner datasets, and accelerated time to insight.

Looking Ahead

Over the next year, IgniteData will focus on:

• Product expansions to support remote patient monitoring and wearables
  
• New strategic partnerships that expand data coverage and interoperability
  
• Growing customer success and support teams to match the increased deployment footprint
  

IgniteData isn’t just automating clinical trial workflows - it’s rewriting the core operating model, transforming data transfer from a task into a utility that quietly powers faster research at scale.